Bristol-Myers Squibb
Executive Summary
Bruce Ross to president, BMS U.S. Pharmaceuticals Group, responsible for the Squibb U.S. Pharmaceutical businesses, Bristol-Myers Oncology Division, Mead Johnson Labs, and medical, marketing, business development and sales services function supporting the pharmaceutical businesses. He reports to Ray Egan, president BMS U.S. Pharmaceuticals, Mead Johnson Nutritionals, Squibb Diagnostics, and Managed Health Care Group. A 29-year veteran who started with Bristol Labs in 1971, Ross became president of Bristol-Myer's U.S. Pharmaceutical Group in 1987. Reporting to him is James Mauzey, who was named president of the BMS U.S. Pharmaceutical Division. Mauzey joined the firm in 1989 from Lederle and most recently had been president of the Squibb U.S. Pharmaceutical Group.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.